Summary

Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Ronald Mitsuyasu, MD

Description

Summary

Long term safety follow-up of Cal-1 recipients

Official Title

Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct

Details

Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced with LVsh5/C46 (Cal-1), a Dual Anti-HIV Gene Transfer Construct

Keywords

HIV-1 Infection, Receipt of Cal-1 Modified Hematopoietic Cellular Products, Blood tests

Eligibility

You can join if…

  • Signed informed consent
  • Previous treatment with the Cal-1 modified hematopoietic cellular products

You CAN'T join if...

  • Inability to understand and provide informed consent

Locations

  • UCLA CARE Center
    Los Angeles California 90035 United States
  • Quest Clinical Research
    San Francisco California 94115 United States

Lead Scientist at UCLA

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Calimmune, Inc.
ID
NCT02390297
Study Type
Observational
Participants
About 11 people participating
Last Updated